Clinical Trials Browser

OTHER × Triple Negative Breast Neoplasms × tislelizumab × Clear all

NCT04802876 2025-03-21

ACROPOLI

Phase 2 Active not recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmSarcomaThoracic

Adenocarcinoma Of Esophagus, Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Uveal Melanoma, Anus Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Neoplasms, Unknown Primary, Sarcoma, Thyroid Neoplasms, Cholangiocarcinoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT06538896 2024-11-26

Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis，an Exploratory, Single-Arm, Multicenter Phase II Clinical Study

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT06448169 2024-06-07

Observational Study on the Sensitivity of Neoadjuvant Immunotherapy in Early Triple-Negative Breast Cancer

Hypersensitivity, Triple Negative Breast Neoplasms

NCT04914390 2024-01-22

NeoATCT

Phase 2 Unknown

Triple Negative Breast Neoplasms

NCT04734262 2023-11-18

SPARK

Phase 2 Unknown

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05746728 2023-04-06

Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer

Phase 1/2 Unknown

Triple Negative Breast Neoplasms

NCT04501523 2023-02-21

Apollo

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT04913571 2021-06-04

TEMPLATE

Phase 2 Unknown

Triple Negative Breast Neoplasms